Aha! The third poster. Thanks for finding this!
This is an outstanding result:
"potent cytolytic activity against triple negative breast cancer and HCC tumor cells. OnCARlytics demonstrated expression of CD19t and robust in vivo anti-tumor efficacy against human HCC tumor xenografts. In summary, CD19 ARTEMIS® T-Cells combined with onCARlytics is a potentially effective immunotherapy strategy for the treatment of patients with HCC and can be applied to other solid tumors."
A potent effect in triple negative breast cancer AND in liver cancer. The Artemis/OnCARlytics combination cert mainly looks like a winner.
Confirmation here that they are highly interested, because they end with: "CD19 ARTEMIS® T-Cells and onCARlytics combination therapy efficacy will be tested in multiple in vivo models."
That sounds like Ph 1 clinical trials to me, against more than one solid tumour type.
Cheers
Dave :
Media Thread, page-7454
-
- There are more pages in this discussion • 7,632 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.5¢ | 5.3¢ | $374.4K | 6.932M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 884300 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 759998 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |